Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday, BidAskClub reports.
Several other brokerages have also recently issued reports on SRPT. Citigroup boosted their price objective on Sarepta Therapeutics from $177.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Morgan Stanley boosted their price objective on Sarepta Therapeutics from $172.00 to $182.00 and gave the company an “overweight” rating in a report on Monday, August 10th. Bank of America cut their price target on Sarepta Therapeutics from $190.00 to $189.00 and set a “buy” rating for the company in a research note on Friday, August 21st. Royal Bank of Canada restated a “buy” rating on shares of Sarepta Therapeutics in a research note on Sunday, October 11th. Finally, Credit Suisse Group lowered Sarepta Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $185.00 to $167.00 in a research note on Thursday, August 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-four have issued a buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $195.48.
Shares of SRPT stock traded up $1.16 on Thursday, hitting $141.49. The company had a trading volume of 474,857 shares, compared to its average volume of 822,776. The firm has a market cap of $11.11 billion, a P/E ratio of -20.16 and a beta of 1.82. The company has a 50-day moving average price of $140.34 and a 200-day moving average price of $145.80. The company has a quick ratio of 6.42, a current ratio of 6.93 and a debt-to-equity ratio of 0.67. Sarepta Therapeutics has a twelve month low of $78.06 and a twelve month high of $175.00.
Trading options can make you serious money, fast… But if you ask anyone on Wall Street… They’ll tell you options are too “complicated” and “risky” for everyday people. Until rookies across the country started doubling their money in two days.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($1.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.20). The company had revenue of $137.36 million during the quarter, compared to analyst estimates of $112.36 million. Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%. Equities research analysts expect that Sarepta Therapeutics will post -7.57 EPS for the current year.
In other news, insider Joseph Bratica sold 1,125 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $155.00, for a total transaction of $174,375.00. Following the transaction, the insider now owns 8,957 shares of the company’s stock, valued at approximately $1,388,335. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Richard Barry sold 30,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $158.50, for a total transaction of $4,755,000.00. Following the transaction, the director now directly owns 3,132,280 shares in the company, valued at approximately $496,466,380. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,125 shares of company stock worth $6,519,375. 5.90% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $30,000. Patriot Financial Group Insurance Agency LLC raised its holdings in Sarepta Therapeutics by 84.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 436 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 200 shares during the period. Pacer Advisors Inc. purchased a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $93,000. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 797.1% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 314 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 279 shares during the period. Finally, Jacobi Capital Management LLC raised its holdings in Sarepta Therapeutics by 712.2% in the 2nd quarter. Jacobi Capital Management LLC now owns 5,734 shares of the biotechnology company’s stock valued at…
Read More: Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Hold at BidaskClub